Table 4.

Intent-to-Treat Summary of Cumulative Adverse Events by Treatment Group for All Randomized Participants

	Atorvastatin (n = 14)
AE categories	1-Month visit	3-Month visit	6-Month visit
Musculoskeletal	3 (21%)	5 (36%)	6 (43%)
Gastrointestinal	3 (21%)	3 (21%)	3 (21%)
Fatigue	0 (0%)	1 (7%)	1 (7%)
Cognitive	0 (0%)	0 (0%)	0 (0%)
Abnormal safety labs	3 (21%)	3 (21%)	3 (21%)
Respiratory	3 (21%)	7 (50%)	8 (57%)
Miscellaneous	4 (29%)	8 (57%)	11 (79%)

	Placebo (n = 13)
Musculoskeletal	0 (0%)	3 (23%)	4 (31%)
Gastrointestinal	2 (15%)	2 (15%)	3 (23%)
Fatigue	1 (8%)	2 (15%)	2 (15%)
Cognitive	1 (8%)	2 (15%)	2 (15%)
Abnormal safety labs	4 (31%)	4 (31%)	4 (31%)
Respiratory	2 (15%)	5 (38%)	6 (46%)
Miscellaneous	2 (15%)	4 (31%)	6 (46%)